Lushova A A, Biazrova M G, Prilipov A G, Sadykova G K, Kopylov T A, Filatov A V
1Institute of Immunology, Federal Medical-Biological Agency of Russia, Moscow, 115478 Russia.
2Ivanovsky Institute of Virology, Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, 123098 Russia.
Mol Biol. 2017;51(6):782-787. doi: 10.1134/S0026893317060103. Epub 2017 Dec 14.
Monoclonal antibodies have found wide applications in the treatment of cancer, as well as of autoimmune, infectious, and other diseases. Several dozen new antibodies are currently undergoing different stages of clinical trials, and some of them will soon be added to the list of immunotherapeutic drugs. Most of these antibodies have been generated using hybridoma technology or a phage display. In recent years, new methods of obtaining human monoclonal antibodies have been actively developing. These methods rely on sequencing immunoglobulin genes from B lymphocytes, as well as on the creation of antibody-secreting stable B-cell lines. The term has already been established in the literature to refer to these approaches. Our review focuses on describing the results obtained by these methods.
单克隆抗体已在癌症治疗以及自身免疫性疾病、感染性疾病和其他疾病的治疗中得到广泛应用。目前有几十种新抗体正处于不同阶段的临床试验中,其中一些很快将被列入免疫治疗药物名单。这些抗体大多是利用杂交瘤技术或噬菌体展示技术产生的。近年来,获取人源单克隆抗体的新方法一直在积极发展。这些方法依赖于对B淋巴细胞的免疫球蛋白基因进行测序,以及创建分泌抗体的稳定B细胞系。文献中已经确立了该术语来指代这些方法。我们的综述重点描述通过这些方法所获得的结果。